Clinical Use and Patentability of Cord Blood

Title:Clinical Use and Patentability of Cord Blood

Volume: 11 Issue: 1

Author(s): Turker Cavusoglu*, Kubilay Dogan Kilic, Gurkan Yigitturk, Canberk Tomruk, Mehmet Turgut and Yigit Uyanikgil

Affiliation:

• Department of Histology and Embryology, Ege University School of Medicine, Izmir,Turkey

Keywords: Clinical use, cord blood, stem cell, umblical cord blood, patent, haematology, haemopoetic diseases.

Abstract: Background: The blood in the umbilical cord that provides the connection between mother and fetus during pregnancy is called cord blood. The blood of umbilical cord which is usually got rid of following birth, is a very rich stem cell source.

Objective: Cord blood collection gives no harm to the mother and baby. Besides, its allogeneic and autologous usage, the most important disadvantage is that the number of cells is insufficient in adults.

Conclusion: Today, it is predominantly used for therapeutic purposes for many diseases. The aim of this review is giving a detailed information about groups of stem cells in cord blood and determining the point of clinical use.

Cite this article as:

Cavusoglu Turker *, Kilic Dogan Kubilay , Yigitturk Gurkan , Tomruk Canberk , Turgut Mehmet and Uyanikgil Yigit , Clinical Use and Patentability of Cord Blood, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) 2017; 11 (1) . https://dx.doi.org/10.2174/1872214812666180314121241